Malta - English - Medicines Authority

actavis group ptc ehf revkjavikurvegi 76-78, 220 hafnarfjordur, iceland - valsartan - capsule - valsartan 40 mg - agents acting on the renin-angiotensin system

Malta - English - Medicines Authority

actavis group ptc ehf revkjavikurvegi 76-78, 220 hafnarfjordur, iceland - valsartan - capsule - valsartan 80 mg - agents acting on the renin-angiotensin system

Malta - English - Medicines Authority

actavis group ptc ehf revkjavikurvegi 76-78, 220 hafnarfjordur, iceland - valsartan - capsule - valsartan 160 mg - agents acting on the renin-angiotensin system

Malta - English - Medicines Authority

jubilant pharmaceuticals nv axxes business park, guldensporenpark 22 – block c, 9820 merelbeke, belgium - valsartan - film-coated tablet - valsartan 40 mg - agents acting on the renin-angiotensin system

Malta - English - Medicines Authority

jubilant pharmaceuticals nv axxes business park, guldensporenpark 22 – block c, 9820 merelbeke, belgium - valsartan - film-coated tablet - valsartan 80 mg - agents acting on the renin-angiotensin system

Malta - English - Medicines Authority

jubilant pharmaceuticals nv axxes business park, guldensporenpark 22 – block c, 9820 merelbeke, belgium - valsartan - film-coated tablet - valsartan 160 mg - agents acting on the renin-angiotensin system

Israel - English - Ministry of Health

a.l. medi-market ltd. - valsartan - film coated tablets - valsartan 160 mg - valsartan - for treatment of hypertension. valsartan-medo is indicated for the treatment of heart failure (nyha class ii-iv) in patients who are intolerant of angiotensin converting enzyme inhibitors. in a controlled clinical trial valsartan-medo signicantly reduced hospitalisations for heart failure. there is no evidence that valsartan-medo provides added benefits when it is used with an adequate dose of an ace inhibitor. valsartan-medo is indicated to improve survival following myocardial infarction in clinically stable patients with signs symptoms or radiological evidence of left ventricular failure and /or with left ventricular systolic dysfunction.

Israel - English - Ministry of Health

a.l. medi-market ltd. - valsartan - film coated tablets - valsartan 80 mg - valsartan - for treatment of hypertension. valsartan-medo is indicated for the treatment of heart failure (nyha class ii-iv) in patients who are intolerant of angiotensin converting enzyme inhibitors. in a controlled clinical trial valsartan-medo signicantly reduced hospitalisations for heart failure. there is no evidence that valsartan-medo provides added benefits when it is used with an adequate dose of an ace inhibitor. valsartan-medo is indicated to improve survival following myocardial infarction in clinically stable patients with signs symptoms or radiological evidence of left ventricular failure and /or with left ventricular systolic dysfunction.

Canada - English - Health Canada

teva canada limited - valsartan; hydrochlorothiazide - tablet - 80mg; 12.5mg - valsartan 80mg; hydrochlorothiazide 12.5mg - angiotensin ii receptor antagonists

Canada - English - Health Canada

teva canada limited - valsartan; hydrochlorothiazide - tablet - 160mg; 12.5mg - valsartan 160mg; hydrochlorothiazide 12.5mg - angiotensin ii receptor antagonists